You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 1
  • 685 European multi-disciplinary tumour boards within the EURACAN network increasingly support management of patients with rare gynaecological tumours: results from 2017–2023 activity

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
14. Organization of gynaecological cancer care
685 European multi-disciplinary tumour boards within the EURACAN network increasingly support management of patients with rare gynaecological tumours: results from 2017–2023 activity
  1. Alice Bergamini1,
  2. Ulrika Joneborg2,
  3. Gloria Marquina3,
  4. Elisa Grassi1,
  5. Emelie Wallin2,
  6. Antonio Casado3,
  7. Olesia Solheim4,
  8. Carolina Maria Sassu5,
  9. Christianne AR Lok6,
  10. Marta Bini7,
  11. Patricia Pautier8,
  12. Frédéric Kridelka9,
  13. Jalid Sehouli10,
  14. Els Van Nieuwenhuysen11,
  15. John Coulter12,
  16. Pierre-Adrien Bolze13,
  17. Coriolan Lebreton14,
  18. Jurgen MJ Piek15,
  19. Isabelle Ray-Coquard16 and
  20. Michael Seckl17
  1. 1Department of Gynaecological Oncology, IRCCS San Raffaele Hospital, Milan, Italy
  2. 2Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden
  3. 3Department of Medical Oncology, Hospital Clinico San Carlos, School of medicine, UCM, IdissC, Madrid, Spain
  4. 4Department of Gynaecological Oncology, Oslo University Hospital, Oslo, Norway
  5. 5Dipartimento Scienze della Salute della Donna, del Bambino e di Sanita` Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
  6. 6Netherlands Cancer Institute, Amsterdam, The Netherlands
  7. 7National Cancer Institute of Milan, Milan, Italy
  8. 8Department of Oncology, Gustave Roussy, Villejuif, France
  9. 9CHU de Liège, Liège, Belgium
  10. 10Department of Gynecology European Competence Center for Ovarian Cancer, Campus Virchow-Klinikum, Charité Medical University, Berlin, Germany
  11. 11Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium
  12. 12Department of Gynaecological Oncology, Cork University Hospital, Cork, Ireland
  13. 13Université Lyon 1 – Hospices Civils de Lyon – Centre Français de Référence des Maladies Trophoblastiques – CICLY EA3738, Lyon, France
  14. 14Institut Bergonié, Bordeaux, France
  15. 15Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, The Netherlands
  16. 16Centre Léon Bérard, Lyon, France
  17. 17Imperial College London, London, UK

Abstract

Introduction/Background The European Reference Network for Rare Adult Cancers (EURACAN) G2 domain deals with rare gynaecological cancers. Within this domain, virtual multi-disciplinary tumour boards (MDTs) were implemented in 2017 to advise on clinical management of patients. Here, we update on the 6-year activity in terms of participation and treatment recommendations.

Methodology EURACAN G2 cross-border MDTs were organized monthly since November 2017 by Karolinska University Hospital, Stockholm, Sweden1. From March 2021 to April 2023, the MDTs were coordinated by Ospedale San Raffaele, Milan, Italy and since March 2023 by Hospital Clinico San Carlos, Madrid, Spain. A standardized form was used for collecting patient data and a summary of cases was circulated to all participants prior to the MDTs. The outcomes, including recommendations for further investigations and treatment, were distributed following each MDT to validate the proposal. The MDT background data and outcomes of discussions were registered in a prospective database.

Results Between November 2017 and October 2023, 67 MDTs were organized with participants from 18 countries and 20 EURACAN centers. 260 individual patients were discussed (median 4 patients/session, range 1–12). Background data are presented in table 1. The number of cases discussed has increased over the years (median/year=46, range 29–82); the number of participants/session has increased over time (median 12, range 11–15). The MDT discussions resulted in a recommendation for pathological review and sequencing in 24% and 9.6% of cases, respectively. Surveillance instead of oncological treatment was recommended to 17% of cases, while off-label treatment and inclusion in a clinical trial were recommended in 12% and 8.5% of cases, respectively. For 58.7% of patients, new treatment opportunities were suggested, compared to the locally proposed management.

Conclusion EURACAN G2 domain MDTs increasingly offers an opportunity for clinical support and formulation of treatment strategies for physicians to manage patients with rare gynecological cancers.

Disclosures No disclosures.

View this table:
Abstract 685 Table 1

https://doi.org/10.1136/ijgc-2024-ESGO.1082

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.